( July 21, 2026, 8:52 AM EDT) -- NEW ORLEANS — The manufacturers of mifepristone, one of two drugs used to induce early termination of pregnancy, and the U.S. Food and Drug Administration filed separate briefs urging the Fifth Circuit U.S. Court of Appeals to affirm a district court’s denial of Louisiana’s motion to stay the FDA’s 2023 decision that removed the in-person dispensing requirement for the drug, arguing that there was no abuse of discretion by the district court and that the state lacks standing to bring the case....